Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (July 2019)
17 slides from Harrow's investor presentation, Jul 31, 2019
Slide 1: August 2019
August 2019
Slide 2: Harbor
/| jo HARBOR
Slide 3: Mayfield Senior Leadership
———SEe Mayfield Senior Leadership Experience Background = Strategic planning, licensing and business development expertise in the life sciences industry = Chief Business Officer, Keryx; Senior VP, Business Development, Melissa Bradford-Klug 20+ years AMAG Pharmaceuticals, VP Business Development & L
Slide 4: Harrow Health, Inc. Overview
Harrow Health, Inc. Overview Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including one of the nation’s leading ophthalmology pharmaceutical businesses, ImprimisRx Harrow’s business model is to Found, Fund and Spin-Out healthcare businesses and fo return capital to s
Slide 5: Mayfield Pharmaceuticals
SSE Mayfield Pharmaceuticals Our vision is to /es by developing products that address significant and conspicuous unmet needs prove women’s Products that Products that enhance women’s health and address large unmet needs in the marketplace. matter Low risk ‘Our development programs focus on using kn
Slide 6: Mayfield's Drug Candidates
Mayfield’s Drug Candidates MAY 88 Lead drug candidate for bacterial vaginosis, a $1 Billion+ market opportunity + A patented new chemical entity with a broad spectrum antimicrobial active « Strong translatable preclinical data in various models and applications * Bacterial vaginosis is most prevalen
Slide 7: MAY-66 for Bacterial Vaginosis
MAY-66 for Bacterial Vaginosis THE PROBLEM: A large percentage of women suffering from Bacterial vaginosis (BV) need more ‘efficacious treatment options ‘+ No treatment options for reoccurrence of bacterial vaginitis “+ Pregnant women have no safe treatment options for BV + Potential embarrassing si
Slide 8: MAY-66 Drug Candidate Overview
MAY-66 DRUG CANDIDATE OVERVIEW + Novel broad spectrum antimicrobial active against all gram positive, gram negative bacteria and fungi + First in class, small molecule + Effective against ALL pathogens associated with vaginitis including multi-resistant bacteria; multi-resistant fungi; microbial bio
Slide 9: MAY-66 Proven Efficacy
— MAY-66 Proven Efficacy In preclinical models, MAY-66 was significantly more effective against all pathogens of BV compared nal therapy Metronoidazole Pathogen Clindamycin Biguanides 2.5256 0125-51 64-256 0.25->256 8.256 1-64 1-256 8-256 025-128
Slide 10: MAY-66 Mouse Model
MAY-66 Mouse Model MAY-66 treatment resulted in complete elimination of BV in 100% of the animals by Day 7 and prevented recurrence of the infection 5 2 G 3 = 80 % 70 §_ 60 8 50 8 5 40 2 30 3 20 § 10 0 BMay-66 ™Mitronidazole mClindamyn = PHMB 10
Slide 11: MAY-44 for Dyspareunia (painful intercourse)
MAY-44 for Dyspareunia (painful intercourse) THE PROBLEM: A large percentage of women suffering from dyspareunia do not have treatments options: “+ No treatment options exist for premenopausal and posimenopausal women + Btiology is different for women depending on the stage of their life + 50-70% of
Slide 12: MAY-44 Drug Candidate Overview
MAY-44 DRUG CANDIDATE OVERVIEW Non-estrogen gel containing a patented pH-balanced formulation of 3.75% lidocaine and excipients designed for use on mucosal surfaces Goestch proof of concept study in 46-patient randomized, double-blinded study in breast cancer survivors. 87.5% reduction in pain durin
Slide 13: MAY-88 for Interstitial Cystitis
MAY-88 for Interstitial Cystitis THE PROBLEM: MAY Tes pareteye yee at foven Gens treed Ore (Clad bette Fase deat et es eover tote debe 88 Oe er rs ar Sears ‘and pelvic pain and is sometimes dascribed a: painful bladder syndrome + Treatment includes pharmacological, intravesical, surgical, electrical
Slide 14: MAY-88 Drug Candidate Overview
MAY-88 DRUG CANDIDATE OVERVIEW First oral anhydrous extended release suspension of pentosan sulphate indicated women that have difficulty swallowing Anecdotal evidence has shown the oral suspension may have favorable pharmacokinetic profile 15 including faster onset and extended release properties t
Slide 15: Summary
Summary LS Mayfield Pharmaceuticals is a women's health focused subsidiary of Harrow Health, Inc. Led by an experienced and preven management team and board of directors Focused on patented 505(b)(2) drugs and new chemical entities with known mechanisms of action Y Sas Potential to disrupt large mul
Slide 16: Timeline and Use of Proceeds
Timeline and Use of Proceeds Patent Protection Target Phase 2 Est. Capital Outlay thru Thro il Completion Value Inflection * Drug Candidate Market Size MAY-66 Paisanae radiereeureerd bractersal wee eres $1B+ 2038 2021 2022 $5.5M - $6.7M MAY-44 Panes pre-and pear iicinpeaisal wali $1.58 2036 2020 202
Slide 17: References
References Sexually Transmitted Diseases, November 2007, Vol. 34, No. 11, p. 864-869 National Salas Perspectives IMS April 2018-March 2019 Sexually Transmitted Diseases, November 2007, Vol. 34, No. 11, p.864-869 National Prescriptions Audit IMS April 2018-March 2019 Sexually Transmitted Diseases, No